Patents by Inventor Giovanni Mistrello

Giovanni Mistrello has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10526365
    Abstract: A method of making and a modified allergen having reduced allergenicity and preserved immunogenicity compared to corresponding native allergenic material. The preserved immunogenicity is elicited by a IgG-mediated antibody response, all or part of the primary amine groups of the lysine residues of the native allergenic material are functionalized with carbamoyl or thiocarbamoyl moieties, and all or part of the primary amine groups of the arginine residues of the carbamoyl- or thiocarbamoyl functionalized allergenic material are further functionalized with dialdehyde or diketal moieties. The raw allergenic material is selected from the group consisting of DP mites extract, Der p1, ovalbumin and Lipid Transfer Protein (LTP), the average percentage of modified primary amine groups of the lysine ranges between 75% and 100%; and the average percentage of the substituted arginine residues ranges between 25% and 10%.
    Type: Grant
    Filed: April 20, 2015
    Date of Patent: January 7, 2020
    Assignee: LOFARMA S.P.A.
    Inventors: Giovanni Mistrello, Daniela Roncarolo, Dario Zanoni, Stefania Zanotta, Paolo Falagiani
  • Patent number: 9957306
    Abstract: Disclosed are hypoallergenic variants of Mal d 1, the major allergen from Malus domestica, and the uses thereof in the treatment of allergic diseases.
    Type: Grant
    Filed: July 31, 2012
    Date of Patent: May 1, 2018
    Assignee: LOFARMA S.P.A.
    Inventors: Giovanni Mistrello, Stefania Zanotta, Daniela Roncarolo
  • Patent number: 9809629
    Abstract: Disclosed are hypoallergenic variants of Phl p 5, the major allergen from Phleum pratense, and the uses thereof in the treatment of allergic diseases.
    Type: Grant
    Filed: December 18, 2012
    Date of Patent: November 7, 2017
    Assignee: LOFARMA S.P.A.
    Inventors: Giovanni Mistrello, Stefania Zanotta, Daniela Roncarolo
  • Publication number: 20150259378
    Abstract: A method of making and a modified allergen having reduced allergenicity and preserved immunogenicity compared to corresponding native allergenic material. The preserved immunogenicity is elicited by a IgG-mediated antibody response, all or part of the primary amine groups of the lysine residues of the native allergenic material are functionalized with carbamoyl or thiocarbamoyl moieties, and all or part of the primary amine groups of the arginine residues of the carbamoyl- or thiocarbamoyl functionalized allergenic material are further functionalized with dialdehyde or diketal moieties. The raw allergenic material is selected from the group consisting of DP mites extract, Der p1, ovalbumin and Lipid Transfer Protein (LTP), the average percentage of modified primary amine groups of the lysine ranges between 75% and 100%; and the average percentage of the substituted arginine residues ranges between 25% and 10%.
    Type: Application
    Filed: April 20, 2015
    Publication date: September 17, 2015
    Inventors: Giovanni MISTRELLO, Daniela RONCAROLO, Dario ZANONI, Stefania ZANOTTA, Paolo FALAGIANI
  • Patent number: 8945574
    Abstract: The invention provides hypoallergenic variants of Bet v 1 major allergen from Betula verrucosa plant pollen and the use thereof for the preventive or therapeutic treatment of allergic diseases.
    Type: Grant
    Filed: December 19, 2006
    Date of Patent: February 3, 2015
    Assignee: Lofarma S.p.A.
    Inventors: Giovanni Mistrello, Stefania Zanotta, Daniela Roncarolo, Paolo Falagiani
  • Publication number: 20140328881
    Abstract: Disclosed are hypoallergenic variants of PhI p 5, the major allergen from Phleum pratense, and the uses thereof in the treatment of allergic diseases.
    Type: Application
    Filed: December 18, 2012
    Publication date: November 6, 2014
    Inventors: Giovanni Mistrello, Stefania Zanotta, Daniela Roncarolo
  • Publication number: 20140294878
    Abstract: Disclosed are hypoallergenic variants of Mal d 1, the major allergen from Malus domestica, and the uses thereof in the treatment of allergic diseases.
    Type: Application
    Filed: July 31, 2012
    Publication date: October 2, 2014
    Applicant: LOFARMA S.P.A
    Inventors: Giovanni Mistrello, Stefania Zanotta, Daniela Roncarolo
  • Patent number: 8637037
    Abstract: The present invention concerns the preparation of purified allergens and allergoids, both derived from whole bee venom, for the desensitization (immunotherapy) of subjects affected by a specific allergy. In particular, the present invention concerns a preparation for immunotherapy based on purified bee venom, characterized in that said bee venom is essentially mellitin-free. In addition, the preparation of a monomeric allergoid obtainable through the carbamylation or thiocarbamylation reaction of said mellitin-free bee venom, is described. Said allergoid, being characterized by reduced IgE-binding activity, may be a safer and more effective candidate for specific immunotherapy.
    Type: Grant
    Filed: December 16, 2008
    Date of Patent: January 28, 2014
    Assignee: Lofarma S.p.A.
    Inventors: Giovanni Mistrello, Daniela Roncarolo, Dario Zanoni, Paolo Falagiani
  • Patent number: 8591907
    Abstract: The invention provides hypoallergenic variants of Bet v 2 major allergen from Betula verrucosa plant pollen and the use thereof for the preventive or therapeutic treatment of allergic diseases.
    Type: Grant
    Filed: September 16, 2008
    Date of Patent: November 26, 2013
    Assignee: Lofarma S.p.A.
    Inventors: Giovanni Mistrello, Stefania Zanotta, Daniela Roncarolo, Paolo Falagiani
  • Publication number: 20120114699
    Abstract: Modified allergens having reduced allergenicity compared to corresponding native allergenic material, wherein all or a part of the primary amine groups of the lysine and arginine residues of the allergenic molecules are functionalized and the modified allergens have the structure wherein R and R2 are independently selected from H, C1-C5 alkyl, phenyl, phenyl substituted in ortho, meta, or para with a hydroxy, C1-C4 alkoxy, halogen, amino, alkylamino, dialkylamino, mercapto, C1-C4 alkylmercapto group; X represents O, S, or NR3, where R3 is H, alkyl with 1-6 carbon atoms, phenyl, or CN; R1 represents H, alkyl with 1-8 carbon atoms, phenyl or arylalkyl with up to 8 carbon atoms, or alkyl containing a heterocyclic ring; prot represents the protein residue of the allergen; n is the number of functionalized arginine groups and ranges between 1 and the number of arginine groups present in the allergen; m is the number of functionalized lysine groups and ranges between 1 and the number of lysine groups present in
    Type: Application
    Filed: October 2, 2009
    Publication date: May 10, 2012
    Applicant: LOFARMA S.P.A.
    Inventors: Giovanni Mistrello, Daniela Roncarolo, Dario Zanoni, Stefania Zanotta, Paolo Falagiani, Pietro Falagiani
  • Publication number: 20100310590
    Abstract: The invention provides hypoallergenic variants of Bet v 2 major allergen from Betula verrucosa plant pollen and the use thereof for the preventive or therapeutic treatment of allergic diseases.
    Type: Application
    Filed: September 16, 2008
    Publication date: December 9, 2010
    Applicant: LOFARMA S.p.A.
    Inventors: Giovanni Mistrello, Stefania Zanotta, Daniela Roncarolo, Paolo Falagiani
  • Publication number: 20100297188
    Abstract: The present invention concerns the preparation of purified allergens and allergoids, both derived from whole bee venom, for the desensitisation (immunotherapy) of subjects affected by a specific allergy. In particular, the present invention concerns a preparation for immunotherapy based on purified bee venom, characterised in that said bee venom is essentially mellitin-free. In addition, the preparation of a monomeric allergoid obtainable through the carbamylation or thiocarbamylation reaction of said mellitin-free bee venom, is described. Said allergoid, being characterised by reduced IgE-binding activity, may be a safer and more effective candidate for specific immunotherapy.
    Type: Application
    Filed: December 16, 2008
    Publication date: November 25, 2010
    Inventors: Giovanni Mistrello, Daniela Roncarolo, Dario Zanoni, Paolo Falagiani
  • Publication number: 20090304752
    Abstract: The invention provides hypoallergenic variants of Bet v 1 major allergen from Betula verrucosa plant pollen and the use thereof for the preventive or therapeutic treatment of allergic diseases.
    Type: Application
    Filed: December 19, 2006
    Publication date: December 10, 2009
    Inventors: Giovanni Mistrello, Stefania Zanotta, Daniela Roncarolo, Paolo Falagiani
  • Patent number: 7029686
    Abstract: Hypoallergenic variants of the major allergen Ph1 p 1 of Phleum pratense plants and their use in the therapy of the allergic diseases is disclosed.
    Type: Grant
    Filed: September 12, 2001
    Date of Patent: April 18, 2006
    Assignee: Consiglio Nazionale Delle Ricerche
    Inventors: Monica Sturaro, Angelo Viotti, Paolo Falagiani, Giovanni Mistrello, Daniela Roncarolo, Stefania Zanotta
  • Patent number: 6800290
    Abstract: Variants of allergens of Dermatophagoides pteronyssinus species with reduced allergenic activity.
    Type: Grant
    Filed: September 12, 2001
    Date of Patent: October 5, 2004
    Assignee: Consiglio Nazionale Delle Ricerche
    Inventors: Monica Sturaro, Angelo Viotti, Paolo Falagiani, Giovanni Mistrello, Daniela Roncarolo, Stefania Zanotta
  • Publication number: 20020064530
    Abstract: Hypoallergenic variants of the major allergen Ph1 p 1 of Phleum pratense plants and their use in the therapy of the allergic diseases is disclosed.
    Type: Application
    Filed: September 12, 2001
    Publication date: May 30, 2002
    Inventors: Monica Sturaro, Angelo Viotti, Paolo Falagiani, Giovanni Mistrello, Daniela Roncarolo, Stefania Zanotta
  • Publication number: 20020054881
    Abstract: Variants of allergens of Dermatophagoides pteronyssinus species with reduced allergenic activity.
    Type: Application
    Filed: September 12, 2001
    Publication date: May 9, 2002
    Inventors: Monica Sturaro, Angelo Viotti, Paolo Falagiani, Giovanni Mistrello, Daniela Roncarolo, Stefania Zanotta
  • Patent number: 5354848
    Abstract: Chemically modified allergens, whose allergenic activity is reduced with respect to that of the corresponding native allergenic material, which are capable of inducing specific antibodies addressed towards said native allergenic material, wherein a portion of the primary amino groups of the protein molecule of the native allergen are chemically modified so as to give simple or substituted carbamylic amino groups, or substituted thiocarbamylic amino groups, or possibly substituted guanidino groups, and process for the production thereof. The allergens so modified are not polymerized with each other, they are soluble in water media, they are resistent to tryptic hydrolysis and they show particularly suitable for being administered in hyposensitizing therapeutic treatments.
    Type: Grant
    Filed: September 26, 1990
    Date of Patent: October 11, 1994
    Assignee: Laboratorio Farmaceutico Lofarma S.r.l.
    Inventors: Paolo Falagiani, Oreste Brenna, Giovanni Mistrello
  • Patent number: 4476111
    Abstract: A new antibiotic, designated S/433, is disclosed which is produced in a microbiological fermentation under controlled conditions using a new strain of Streptomyces. This new antibiotic is active against gram-positive and gram-negative bacteria and is also active in inhibiting the growth of transplanted tumors.
    Type: Grant
    Filed: October 19, 1981
    Date of Patent: October 9, 1984
    Assignee: Gruppo Lepetit S.p.A.
    Inventors: Carolina Coronelli, Angelo Borghi, Giorgio Pirali, Giovanni Mistrello